Cart
sales@molnova.com
SU 5616
CAS No. 186611-58-5
SU 5616( —— )
Catalog No. M36392 CAS No. 186611-58-5
SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 62 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 169 | In Stock |
|
| 50MG | 253 | In Stock |
|
| 100MG | 365 | In Stock |
|
| 200MG | 511 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU 5616
-
NoteResearch use only, not for human use.
-
Brief DescriptionSU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.
-
DescriptionSU 5616 is an organic compound. SU 5616 potentially modulates tyrosine kinase signal transduction, and regulates abnormal cell proliferation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetTyrosinase
-
RecptorTyrosine Kinases
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number186611-58-5
-
Formula Weight261.73
-
Molecular FormulaC13H8ClNOS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 15.62 mg/mL (59.68 mM; Ultrasonic (<60°C)
-
SMILESC(=C1C=2C(NC1=O)=CC=C(Cl)C2)C3=CC=CS3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tang Peng Cho, et al. Indolinone compounds capable of modulating tyrosine kinase signal transduction: World Intellectual Property Organization, WO9640116 A1. 1996-12-19.
molnova catalog
related products
-
Tafetinib
Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.
-
NDI-034858
NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseases caused by aberrant expression of IL12 and IL23.
-
Ropsacitinib
Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).
